Lyra Therapeutics, Inc. (LYRA) — Capital Expenditures
| Fiscal Year | Capital Expenditures | Change YoY |
|---|---|---|
| 2025 | $116.0K | -95.0% |
| 2024 | $2.34M | +123.3% |
| 2023 | $1.05M | +538.4% |
| 2022 | $164.0K | -95.2% |
| 2021 | $3.38M | +90.7% |
| 2020 | $1.77M | +741.2% |
| 2019 | $211.0K | — |
| Fiscal Year | Capital Expenditures | Change YoY |
|---|---|---|
| 2025 | $116.0K | -95.0% |
| 2024 | $2.34M | +123.3% |
| 2023 | $1.05M | +538.4% |
| 2022 | $164.0K | -95.2% |
| 2021 | $3.38M | +90.7% |
| 2020 | $1.77M | +741.2% |
| 2019 | $211.0K | — |